Nestlé: to invest 200m dollars in Aimmune Therapeutics
(CercleFinance.com) - Nestlé Health Science (NHSc) has announced that it is making an additional 200 million dollar investment in Aimmune Therapeutics, a California-based biopharmaceutical company.
This company develops and markets treatments for life-threatening food allergies.
LHNC first invested in Therapeutics Aimmune in 2016, having invested a total of 473 million dollars to date.
This additional capital will strengthen of Aimmune Therapeutics' financial position as the company prepares for the launch of PALFORZIA, the first drug approved by the US Food and Drug Administration for food allergies in children and teenagers, the group said.
Investing in food allergy therapies is a natural extension of the NHSc's current pediatric food allergy portfolio, management added.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This company develops and markets treatments for life-threatening food allergies.
LHNC first invested in Therapeutics Aimmune in 2016, having invested a total of 473 million dollars to date.
This additional capital will strengthen of Aimmune Therapeutics' financial position as the company prepares for the launch of PALFORZIA, the first drug approved by the US Food and Drug Administration for food allergies in children and teenagers, the group said.
Investing in food allergy therapies is a natural extension of the NHSc's current pediatric food allergy portfolio, management added.
Copyright (c) 2020 CercleFinance.com. All rights reserved.